GSK to Pay $1 Billion for Synta Melanoma Drug
In a blockbuster codevelopment deal, GlaxoSmithKline gains rights to an innovative Phase III melanoma drug.
Putting the Pressure On
Swiss drug maker gears up to launch first in class Tekturna.
Patients Are Playing Doctor on the Web. It is a Whole New Game for Pharma.
Log on to CrazyMeds.org. Find out what patients say about your drugs, and what they think doctors and pharma don’t tell them.
